Stocks in play: Entheon Biomedical Corp.

Announced that its expanded psychedelics genetic testing panel, developed by its wholly-owned subsidiary, HaluGen Life Sciences Inc., is now available for sale in Canada and the United States. Entheon, a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, via its Subsidiary HaluGen Life Sciences, has expanded its genetic test panel to include the CYP2D6 gene, a marker indicating the metabolism of LSD, MDMA and ayahuasca. Entheon Biomedical Corp shares C.ENBI are trading down $0.03 at $0.39.

Read:

• As Crypto Mining Undergoes a Sustainable Renaissance, Newer, Greener Operations Arise

• Oncology Drug Developers Looking at Significant Projected Growth Through 2030

• Plant-Based Meats Continue to Sprout Growing Revenues on Year-Over-Year Basis

• No Apparent Need to Panic Over Omicron as Vaccine Developers Are on the Case

• Plant-Based Meats Market Projected to Hit $162 Billion by 2030, as New Products Launch